Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Docetaxel

- PMLiVE

New antibiotic compound could potentially treat lethal hospital infections

Zosurabalpin successfully eliminated the multi-resistant A baumannii bacteria

- PMLiVE

MHRA approves Menarini Stemline’s Korserdu for advanced or metastatic breast cancer

More than 55,000 new cases of breast cancer are diagnosed each year in the UK

- PMLiVE

Study programme to investigate blocking brain inflammation in Parkinson’s patients

If successful, the findings could lead to new medicines to treat the neurological disease

- PMLiVE

ICR study increases understanding of advanced breast cancer complication

Breast cancer leptomeningeal metastasis affects one in 20 people with metastatic cases

- PMLiVE

Physical activity could reduce breast cancer risk in women before menopause

The disease is responsible for around 47,000 new cases in the UK every year

- PMLiVE

Roche shares positive late-stage results for inavolisib combination in advanced breast cancer

About 290,000 people in the US will be diagnosed with breast cancer in 2023

- PMLiVE

Roche to acquire Carmot Therapeutics in deal worth up to $3.1bn

The company will gain access to a portfolio of incretin-based therapies for diabetes and obesity

- PMLiVE

AstraZeneca’s Truqap plus Faslodex receives FDA approval for advanced breast cancer

About 290,000 people in the US will be diagnosed with breast cancer in 2023

- PMLiVE

Roche’s subcutaneous Tecentriq recommended by CHMP for multiple cancer types

The formulation can cut treatment time by approximately 80% compared to intravenous infusion

- PMLiVE

MHRA authorises anastrozole to prevent breast cancer in post-menopausal women

The treatment could help prevent around 2,000 breast cancer cases in England

- PMLiVE

Roche collaborates with Ibex and Amazon Web to improve cancer diagnosis

Integrated artificial intelligence-based tools will support clinicians’ decisions in cancer diagnosis

- PMLiVE

Roche to acquire Telavant in deal worth over $7.1bn

The drugmaker will gain access to an experimental treatment for inflammatory bowel disease

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links